Clinical Report: Complete Pathological Response to Neoadjuvant Ensartinib
Overview
This case study presents the first documented instance of a stage IIIB ALK-positive lung squamous cell carcinoma achieving complete pathological response following neoadjuvant treatment with ensartinib. The patient exhibited significant tumor shrinkage and underwent successful surgical resection with no evidence of recurrence at 12 months post-operation.
Background
ALK-positive lung squamous cell carcinoma (LSCC) is rare, with an incidence of less than 1%. The efficacy of neoadjuvant ALK inhibitors like ensartinib in this context has not been extensively studied. Given the poor prognosis associated with ALK rearrangements, exploring targeted therapies in the neoadjuvant setting is crucial for improving outcomes in this patient population.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
The patient was a 65-year-old female diagnosed with stage IIIB ALK-positive LSCC.
Neoadjuvant treatment with ensartinib led to a rapid partial response after four weeks.
After eight weeks of treatment, the tumor was downstaged to a resectable status.
Postoperative examination confirmed a complete pathological response with no tumor cells detected.
The patient received adjuvant ensartinib and showed no evidence of recurrence at 12 months follow-up.
Clinical Implications
This case suggests that neoadjuvant ensartinib may be a viable treatment option for patients with locally advanced, resectable ALK-positive LSCC. Further studies are warranted to establish the broader applicability of this approach.
Conclusion
The successful outcome in this case highlights the potential of neoadjuvant ensartinib in treating ALK-positive LSCC, warranting further investigation into its role in clinical practice.
